These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
114 related articles for article (PubMed ID: 11191685)
1. [Dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity]. Foa C; Bondiau PY; Largillier R; Milano G; Magné N Rev Med Interne; 2000 Dec; 21(12):1134-5. PubMed ID: 11191685 [No Abstract] [Full Text] [Related]
2. Impact of platinum complexes on dihydropyrimidine dehydrogenase activity in 5-fluorouracil-treated patients. Magné N; Pivot X; Etienne-Grimaldi MC; François E; Renée N; Thyss A; Schneider M; Demard F; Milano G Ann Oncol; 2003 Aug; 14(8):1329-30. PubMed ID: 12881401 [No Abstract] [Full Text] [Related]
3. Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients. Celik I; Kars A; Guc D; Tekuzman G; Ruacan S Cancer Invest; 2002; 20(3):333-9. PubMed ID: 12025228 [TBL] [Abstract][Full Text] [Related]
4. [Severe 5-fluorouracil toxicity in a woman treated for breast cancer with concurrent osteogenesis imperfecta and dehydrogenase deficiency]. Beuzeboc P; Pierga JY; Lyonnet DS; Couturier J; Pouillart P Bull Cancer; 1996 Apr; 83(4):324-7. PubMed ID: 8680084 [TBL] [Abstract][Full Text] [Related]
5. Severe 5-fluorouracil toxicity possibly secondary to dihydropyrimidine dehydrogenase deficiency in a breast cancer patient with osteogenesis imperfecta. Beuzeboc P; Pierga JY; Stoppa-Lyonnet D; Etienne MC; Milano G; Pouillart P Eur J Cancer; 1996 Feb; 32A(2):369-70. PubMed ID: 8664058 [No Abstract] [Full Text] [Related]
6. Heterozygosity for a point mutation in an invariant splice donor site of dihydropyrimidine dehydrogenase and severe 5-fluorouracil related toxicity. Van Kuilenburg AB; Vreken P; Beex LV; Meinsma R; Van Lenthe H; De Abreu RA; Van Gennip AH Adv Exp Med Biol; 1998; 431():293-8. PubMed ID: 9598078 [No Abstract] [Full Text] [Related]
7. Severe 5-fluorouracil toxicity in a patient with decreased dihydropyrimidine dehydrogenase activity. Lyss AP; Lilenbaum RC; Harris BE; Diasio RB Cancer Invest; 1993; 11(2):239-40. PubMed ID: 8462026 [No Abstract] [Full Text] [Related]
8. Severe 5-fluorouracil toxicity secondary to dihydropyrimidine dehydrogenase deficiency. A potentially more common pharmacogenetic syndrome. Harris BE; Carpenter JT; Diasio RB Cancer; 1991 Aug; 68(3):499-501. PubMed ID: 1648430 [TBL] [Abstract][Full Text] [Related]
16. Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer. Humerickhouse RA; Dolan ME; Haraf DJ; Brockstein B; Stenson K; Kies M; Sulzen L; Ratain MJ; Vokes EE Clin Cancer Res; 1999 Feb; 5(2):291-8. PubMed ID: 10037177 [TBL] [Abstract][Full Text] [Related]
17. Role of dihydropyrimidine dehydrogenase activity in patients with esophageal cancer. Saeki H; Ito S; Futatsugi M; Kimura Y; Ohga T; Sugimachi K Anticancer Res; 2002; 22(6B):3789-92. PubMed ID: 12552994 [TBL] [Abstract][Full Text] [Related]
18. Technical aspects of intraperitoneal chemotherapy in abdominal carcinomatosis. Braly P; Doroshow J; Hoff S Gynecol Oncol; 1986 Nov; 25(3):319-33. PubMed ID: 3781342 [TBL] [Abstract][Full Text] [Related]